TZIELD

This brand name is authorized in United States.

Active ingredients

The drug TZIELD contains one active pharmaceutical ingredient (API):

1	Teplizumab UNII S4M959U2IJ - TEPLIZUMAB
	Teplizumab-mzwv binds to CD3 (a cell surface antigen present on T lymphocytes) and delays the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 type 1 diabetes. The mechanism may involve partial agonistic signaling and deactivation of pancreatic beta cell autoreactive T lymphocytes. Teplizumab-mzwv leads to an increase in the proportion of regulatory T cells and of exhausted CD8+ T cells in peripheral blood.
	Read more about Teplizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TZIELD Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10XX01		A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10X Other drugs used in diabetes → A10XX Other drugs used in diabetes
Discover more medicines within A10XX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	73650-316